Best medication for menopause and hot flashes, honestly
Menopausal hot flashes have more genuinely effective treatments than most people realize — and the most effective, hormone therapy, is also the most misunderstood. This page compares the main options the way a careful prescriber would: what works best, who each is for, and every FDA boxed warning stated plainly. pharmaranks rates medicines on FDA recall-safety data and does not sell them or give medical advice — treat this as preparation for a conversation with your prescriber, not a substitute for one.
Hormone therapy is the most effective treatment — and the fear of it is largely out of date
Hot flashes come from estrogen withdrawal: as levels fall, the brain's thermostat in the hypothalamus becomes unstable and misreads a normal body temperature as too hot, setting off the flush and sweat. Replacing estrogen corrects the cause directly, which is why it relieves hot flashes better than anything else available. The caution most women remember traces to the early-2000s Women's Health Initiative — but that trial skewed old (average age 63, many more than a decade past menopause), and its risk numbers do not transfer to women who start therapy near menopause. The Menopause Society's current position is that for healthy women under 60, or within 10 years of their last period, the benefits of hormone therapy generally outweigh the risks for bothersome hot flashes. For those who cannot or would rather not take estrogen, there are real non-hormonal options: an FDA-approved low-dose SSRI (Brisdelle), two drugs that target the same brain pathway without hormones (Veozah, and the newer Lynkuet, approved in 2025), and well-studied off-label choices. Systemic estrogen, Brisdelle and Veozah each carry a boxed warning; Lynkuet, the newest, does not — which is exactly why the right choice is personal.
CBT, hypnosis and lifestyle measures
Non-drug
Not a medication. Cognitive behavioral therapy (CBT) and clinical hypnosis are both endorsed by the menopause guideline to reduce how much hot flashes bother you, with no drug risk — a sensible first step for milder symptoms or anyone who prefers to avoid drugs. Practical measures help too: dress in layers, keep rooms cool, and cut the personal triggers many women notice (alcohol, caffeine, spicy food). These lower the burden; they do not replace estrogen for severe, frequent flashes.
Estradiol patch (Climara)
Hormone therapy — estrogen
Estrogen is the most effective treatment for hot flashes — nothing else matches it — because it replaces exactly what the body is withdrawing. A transdermal patch delivers estradiol through the skin and bypasses the liver, which may carry a lower blood-clot risk than estrogen swallowed as a pill. FDA BOXED WARNING: unopposed estrogen raises the risk of endometrial cancer in a woman who still has a uterus, and the Women's Health Initiative linked estrogen to stroke, blood clots, probable dementia over age 65, and — mainly in the estrogen-plus-progestogen arm — breast cancer. It is contraindicated after breast or other estrogen-dependent cancer, after a clot, stroke or heart attack, in active liver disease, and with unexplained vaginal bleeding. Estrogen alone is only for women without a uterus; if you have a uterus you must add a progestogen.
Estrogen plus a progestogen
Hormone therapy — estrogen + progestogen
If you have a uterus, a progestogen (for example micronized progesterone, or a combined patch) is added to the estrogen to protect the womb lining — this is what removes the endometrial-cancer risk of estrogen used alone. It carries the SAME FDA BOXED WARNING as estrogen: cardiovascular events (clots, stroke, heart attack), probable dementia over 65, breast cancer and endometrial cancer. The breast-cancer and cardiovascular signal in the WHI was clearest in this estrogen-plus-progestogen combination, and it rose with age and years since menopause — which is why the guideline reserves the favorable benefit-risk balance for healthy women under 60 or within 10 years of their last period.
Fezolinetant (Veozah)
Non-hormonal — NK3 antagonist (FDA-approved)
A newer, hormone-free option approved in 2023. It blocks the neurokinin-3 (NK3) receptor in the brain's temperature-control center — the same pathway that goes haywire when estrogen falls — so it works without touching hormones, which makes it attractive after breast cancer. FDA BOXED WARNING: risk of liver injury (hepatotoxicity). You must have liver blood tests before starting, then monthly for the first three months and again at six and nine months; it is not started if liver enzymes or bilirubin are already raised, and is stopped at once for any sign of liver trouble. The dose is 45 mg once a day.
Paroxetine 7.5 mg (Brisdelle)
Non-hormonal — SSRI (FDA-approved)
The first non-hormonal drug the FDA approved specifically for moderate-to-severe hot flashes. It is a low 7.5 mg dose of the SSRI paroxetine — below the antidepressant dose — and is not approved to treat depression or any psychiatric condition. FDA BOXED WARNING: SSRIs increased suicidal thoughts and behavior in children and young adults; watch for mood changes, and do not stop abruptly. One important caution: paroxetine strongly blocks the CYP2D6 enzyme that switches tamoxifen on, so it is generally avoided in women taking tamoxifen for breast cancer — venlafaxine is the preferred alternative there.
Venlafaxine (Effexor XR)
Non-hormonal — SNRI (off-label)
Not FDA-approved for hot flashes but one of the best-studied non-hormonal options, and the usual first choice for women who cannot take estrogen — including breast cancer survivors on tamoxifen, because unlike paroxetine it does not meaningfully interfere with it. A low extended-release dose is typical. It carries the SAME antidepressant-class FDA BOXED WARNING for suicidal thoughts in young people as Brisdelle; it can raise blood pressure at higher doses, and its short half-life makes stopping without a taper uncomfortable, so do not stop abruptly.
Gabapentin (Gralise)
Non-hormonal — gabapentinoid (off-label)
An off-label choice that shines for one situation: hot flashes that wreck sleep. Gabapentin is sedating, so a bedtime dose can blunt night sweats and help you stay asleep. It has NO boxed warning — but the FDA does warn of serious breathing problems when it is combined with opioids, alcohol or other sedatives, and it commonly causes drowsiness and dizziness; the dose is lowered if your kidneys are impaired, since the drug leaves the body through them. Gralise is a once-daily form taken with the evening meal.
How to choose
The honest way to narrow it down — matched to your situation, not a ranking. These are common scenarios, not a complete rulebook; the final choice is a prescriber’s.
- You have a uterus, are under 60 or within 10 years of menopause, and flashes are frequent or severe
- Estrogen plus a progestogen — the most effective option, with a benefit-risk balance the guideline considers favorable at your age
- You have had a hysterectomy (no uterus)
- Estrogen alone, such as a transdermal estradiol patch — no progestogen needed, and the patch may carry a lower clot risk than pills
- You cannot or prefer not to take hormones and want an FDA-approved drug
- Brisdelle (low-dose paroxetine), or Veozah (fezolinetant) if you would rather avoid an antidepressant and can commit to the liver monitoring
- You are a breast cancer survivor, especially taking tamoxifen
- Venlafaxine or Veozah — avoid paroxetine, which blunts tamoxifen; systemic hormones are generally off the table
- Night sweats are the main thing ruining your sleep
- Gabapentin (Gralise) at bedtime, on its own or added to another treatment
- Your flashes are mild, or you want to try a drug-free route first
- CBT or clinical hypnosis plus trigger-avoidance and cooling measures
- Your main complaint is vaginal dryness or painful sex, not flashes
- Low-dose vaginal estrogen — it relieves local symptoms with little absorbed into the body; its label still carries the estrogen class warning, but the systemic dose is small
Menopause and hot flashes medications at a glance
| Medication | Type | FDA-approved for hot flashes? | Boxed warning | Best when |
|---|---|---|---|---|
| Estradiol patch (Climara) | Hormone — estrogen | Yes | Yes — cancer, clots, dementia | No uterus (post-hysterectomy); most effective |
| Estrogen + progestogen | Hormone — combined | Yes | Yes — same class warning | You have a uterus; most effective |
| Brisdelle (paroxetine 7.5 mg) | Non-hormonal — SSRI | Yes | Yes — suicidality (SSRI class) | Want an FDA-approved non-hormonal; not on tamoxifen |
| Veozah (fezolinetant) | Non-hormonal — NK3 blocker | Yes | Yes — liver injury | Avoiding hormones; can commit to liver labs |
| Venlafaxine (off-label) | Non-hormonal — SNRI | No (off-label) | Yes — suicidality (antidepressant) | Cannot take hormones; on tamoxifen |
| Gabapentin (Gralise, off-label) | Non-hormonal — gabapentinoid | No (off-label) | No boxed warning | Night sweats wrecking sleep |
| CBT / hypnosis + lifestyle | Non-drug | N/A | None (not a drug) | Mild symptoms or a drug-free preference |
What to expect
Hormone therapy usually begins easing hot flashes within a week or two and reaches its full effect over about four to eight weeks; the non-hormonal drugs work on a similar timescale, often with noticeable benefit in the first couple of weeks. There is no single best choice for everyone — the guideline selects by your age, whether you have a uterus, your other health conditions, and what monitoring you can commit to (Veozah, for instance, requires scheduled liver blood tests). Doses are usually started low and adjusted. Because pharmaranks rates medicines on FDA recall-safety data and does not give medical advice, use this to build your questions; the actual choice, dose and monitoring belong to you and a licensed prescriber.
When to get medical help
- Any unexplained or new vaginal bleeding while on hormone therapy — it needs prompt evaluation to rule out endometrial cancer, which is part of estrogen's boxed warning.
- Signs of a clot or stroke on estrogen: sudden leg swelling or pain, chest pain, shortness of breath, a sudden severe headache, vision loss, or one-sided weakness or slurred speech — call 911.
- A new breast lump, or being offered hormones despite a history of breast cancer, a past clot, stroke or heart attack, or liver disease — these are contraindications, not cautions.
- Yellowing skin or eyes, dark urine, right-upper belly pain, nausea or unusual tiredness on Veozah (fezolinetant) — stop it and get liver tests; hepatotoxicity is its boxed warning.
- New or worsening depression, agitation, or thoughts of self-harm after starting Brisdelle (paroxetine) or venlafaxine — the antidepressant-class boxed warning; do not stop either drug abruptly.
- Extreme drowsiness, confusion or slow, shallow breathing on gabapentin (Gralise) — the danger is much higher if it is combined with opioids, alcohol or other sedatives.
- A spreading rash, facial or throat swelling, or trouble breathing after any new medicine — a possible severe allergic reaction; get emergency care.
Frequently asked questions
Isn't hormone therapy dangerous — didn't a major study link it to cancer and heart attacks?
That fear comes from the 2002 Women's Health Initiative, whose participants averaged age 63 — many more than a decade past menopause. In that older group the estrogen-plus-progestogen arm showed small increases in breast cancer, stroke and clots. For healthy women who start near menopause (under 60 or within 10 years of their last period), The Menopause Society concludes the benefits generally outweigh the risks for bothersome hot flashes. Risk still rises with age, having a uterus, and personal history — so it is an individual decision, not a blanket yes or no.
Which non-hormonal drugs are FDA-approved for hot flashes?
Brisdelle — a low 7.5 mg dose of the SSRI paroxetine — was the first non-hormonal medicine FDA-approved specifically for moderate-to-severe hot flashes. Veozah (fezolinetant), approved in 2023, is a newer FDA-approved non-hormonal option in a different class (an NK3-receptor blocker), and Lynkuet (elinzanetant), approved in 2025, is a third FDA-approved non-hormonal drug in the same NK-blocker family. Venlafaxine and gabapentin also work but are used off-label, meaning the FDA has not approved them for this specific use.
Do I need a progestogen with my estrogen?
Only if you still have a uterus. Estrogen used alone thickens the womb lining and raises endometrial-cancer risk — that is part of the boxed warning — so a progestogen is added to protect it. If you have had a hysterectomy, you take estrogen alone and skip the progestogen.
Which options are safe if I've had breast cancer?
Systemic hormones are generally avoided after breast cancer, so non-hormonal choices are used instead: venlafaxine, gabapentin, or Veozah. One key point — if you take tamoxifen, avoid paroxetine (Brisdelle), because it blunts tamoxifen's activation; venlafaxine is the usual non-hormonal choice there. Discuss any option with your oncology team.
Are 'bioidentical' or compounded hormones safer than regular hormone therapy?
FDA-approved estradiol patches and gels are already bioidentical — chemically identical to the body's own estrogen — and are tested for dose and purity. Custom-compounded 'bioidentical' hormones from a compounding pharmacy are not FDA-approved, not tested for consistency, and carry the same risks as any estrogen, despite marketing that suggests otherwise.
How long can I stay on hormone therapy?
There is no fixed stop date. Guidelines favor the lowest effective dose for as long as the benefits outweigh the risks for you, reviewed with your prescriber periodically. Some women taper off after a few years as flashes fade; others continue longer. It is an ongoing conversation, not a countdown.
Do black cohosh, soy, or other supplements help hot flashes?
The evidence is weak and inconsistent, and supplements are not FDA-approved for hot flashes. Black cohosh in particular has rare reports of liver injury. If flashes are disrupting your life, the treatments on this page have far stronger evidence — talk to a prescriber before relying on a supplement.
Guides for these medications
Sources
Treatment-role framing follows standard US clinical guidelines; each drug links to its FDA label and our rating. This is general reference information, not medical advice, and not a recommendation to take any drug — the choice is a decision to make with a clinician. If you are in crisis, call or text 988 (the US Suicide & Crisis Lifeline).